BDC-3042
BBI-20233042
Phase 1 small_molecule terminated
Quick answer
BDC-3042 for Triple Negative Breast Cancer is a Phase 1 program (small_molecule) at Bolt Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bolt Biotherapeutics
- Indication
- Triple Negative Breast Cancer
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated